featured
SGLT2 Inhibitors and GLP-1 Receptor Agonists for T2D
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
BMJ: British Medical Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sodium-Glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
BMJ 2021 Jan 13;372(xx)m4573, SC Palmer, B Tendal, RA Mustafa, PO Vandvik, S Li, Q Hao, D Tunnicliffe, M Ruospo, P Natale, V Saglimbene, A Nicolucci, DW Johnson, M Tonelli, MC Rossi, SV Badve, Y Cho, AC Nadeau-Fredette, M Burke, LI Faruque, A Lloyd, N Ahmad, Y Liu, S Tiv, T Millard, L Gagliardi, N Kolanu, RD Barmanray, R McMorrow, AK Raygoza Cortez, H White, X Chen, X Zhou, J Liu, AF Rodríguez, AD González-Colmenero, Y Wang, L Li, S Sutanto, RC Solis, F Díaz González-Colmenero, R Rodriguez-Gutierrez, M Walsh, G Guyatt, GFM StrippoliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.